Analysts See $0.90 EPS for ANI Pharmaceuticals Inc (ANIP)

November 1, 2017 - By Adrian Mccoy

 Analysts See $0.90 EPS for ANI Pharmaceuticals Inc (ANIP)
Investors sentiment decreased to 1.06 in 2017 Q2. Its down 0.34, from 1.4 in 2017Q1. It dropped, as 20 investors sold ANI Pharmaceuticals Inc shares while 42 reduced holdings. 17 funds opened positions while 49 raised stakes. 6.39 million shares or 4.42% more from 6.12 million shares in 2017Q1 were reported.
Thomson Horstmann & Bryant Inc invested 0.08% of its portfolio in ANI Pharmaceuticals Inc (NASDAQ:ANIP). State Street Corp invested 0% in ANI Pharmaceuticals Inc (NASDAQ:ANIP). Wells Fargo Mn holds 16,058 shares. Guggenheim Limited Liability Com owns 0.01% invested in ANI Pharmaceuticals Inc (NASDAQ:ANIP) for 52,389 shares. Cadence Capital Management Ltd Liability has invested 0.02% in ANI Pharmaceuticals Inc (NASDAQ:ANIP). Pnc Services Group Inc stated it has 0% of its portfolio in ANI Pharmaceuticals Inc (NASDAQ:ANIP). Amer Gru has 6,009 shares for 0% of their portfolio. 80,585 are owned by Bancorporation Of America Corporation De. Nationwide Fund Advisors invested in 0% or 16,669 shares. The Michigan-based Ls Invest Advsrs Ltd Llc has invested 0% in ANI Pharmaceuticals Inc (NASDAQ:ANIP). 8 are held by Winslow Evans & Crocker Inc. Dimensional Fund Advisors L P has invested 0.01% in ANI Pharmaceuticals Inc (NASDAQ:ANIP). Jpmorgan Chase Company owns 0% invested in ANI Pharmaceuticals Inc (NASDAQ:ANIP) for 10,827 shares. California-based Endurant Capital Management Lp has invested 0.21% in ANI Pharmaceuticals Inc (NASDAQ:ANIP). Moreover, Etrade Capital Mgmt Limited Liability has 0.02% invested in ANI Pharmaceuticals Inc (NASDAQ:ANIP) for 12,990 shares.

Analysts await ANI Pharmaceuticals Inc (NASDAQ:ANIP) to report earnings on November, 2. They expect $0.90 EPS, down 11.76 % or $0.12 from last year’s $1.02 per share. ANIP’s profit will be $10.47 million for 16.13 P/E if the $0.90 EPS becomes a reality. After $0.88 actual EPS reported by ANI Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts 2.27 % EPS growth. The stock decreased 0.82% or $0.48 during the last trading session, reaching $58.08. About shares traded. ANI Pharmaceuticals Inc (NASDAQ:ANIP) has declined 0.02% since November 1, 2016 and is downtrending. It has underperformed by 16.72% the S&P500.

ANI Pharmaceuticals Inc (NASDAQ:ANIP) Ratings Coverage

Among 6 analysts covering ANI Pharma (NASDAQ:ANIP), 4 have Buy rating, 0 Sell and 2 Hold. Therefore 67% are positive. ANI Pharma had 17 analyst reports since July 31, 2015 according to SRatingsIntel. The stock of ANI Pharmaceuticals Inc (NASDAQ:ANIP) has “Buy” rating given on Friday, November 13 by Standpoint Research. The rating was initiated by Raymond James with “Strong Buy” on Thursday, June 23. The rating was upgraded by Oppenheimer to “Perform” on Tuesday, July 19. The company was maintained on Friday, August 5 by Oppenheimer. The stock of ANI Pharmaceuticals Inc (NASDAQ:ANIP) earned “Neutral” rating by TH Capital on Wednesday, February 22. The firm has “Buy” rating given on Monday, September 28 by TH Capital. TH Capital maintained the stock with “Neutral” rating in Tuesday, August 4 report. As per Tuesday, May 24, the company rating was downgraded by Standpoint Research. The firm earned “Buy” rating on Wednesday, September 2 by TheStreet. The stock of ANI Pharmaceuticals Inc (NASDAQ:ANIP) earned “Buy” rating by Canaccord Genuity on Monday, October 16.

ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company. The company has market cap of $675.96 million. The Firm is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. It has a 128.89 P/E ratio. The Firm focuses on areas, including controlled substances, anti-cancer , hormones and steroids, and complex formulations.

More important recent ANI Pharmaceuticals Inc (NASDAQ:ANIP) news were published by: which released: “Wall Street’s M&A Chatter From October 13-15: T-Mobile-Sprint, Radius Health …” on October 16, 2017, also published article titled: “ANI Pharmaceuticals Valued Cheaply Ahead Of Re-Commercialization Of …”, published: “ANI Pharmaceuticals’ Hidden Value” on October 03, 2017. More interesting news about ANI Pharmaceuticals Inc (NASDAQ:ANIP) was released by: and their article: “The Case For A Pending Partnership Between Ani Pharmaceuticals And AbbVie” with publication date: June 19, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.